Medication use for the treatment of diabetes in obese individuals

Diabetologia
J P Wilding

Abstract

Obesity is a major cause of type 2 diabetes and may complicate type 1 diabetes. Weight loss for obese individuals with diabetes has many health benefits, often leads to improvement in glucose control and sometimes, in type 2 diabetes, near normalisation of abnormal glucose metabolism. Weight loss is difficult to maintain and attempts to lose weight may be undermined by some diabetes treatments such as sulfonylureas, thiazolidinediones and insulin. Whilst lifestyle support should be the primary approach to aid individuals who wish to lose weight, pharmacological approaches can also be considered. These include choosing glucose-lowering drugs or drug combinations that are weight neutral or result in weight loss or prescribing drugs that are specifically approved as anti-obesity medication. Given that some of the newer glucose-lowering medications that cause weight loss, such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2i), are also being used or considered for use as anti-obesity drugs, it seems that the distinction between glucose-lowering medication and weight loss medication is becoming blurred. This review discusses the main pharmacological approaches that can be...Continue Reading

References

May 1, 1988·The Journal of Clinical Endocrinology and Metabolism·R R HenryK Griver
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN Diabetes Control and Complications Trial Research GroupC Siebert
Mar 2, 2005·International Journal of Obesity : Journal of the International Association for the Study of Obesity·J RuofA Maetzel
Sep 20, 2006·International Journal of Clinical Practice·J Wilding
Oct 11, 2007·Diabetes, Obesity & Metabolism·David Russell-Jones, Rehman Khan
Jan 10, 2012·Diabetes, Obesity & Metabolism·J JelsingL Bjerre Knudsen
Aug 24, 2012·Disease Models & Mechanisms·R John RodgersJohn P H Wilding
Jun 26, 2013·The New England Journal of Medicine·Rena R WingSusan Z Yanovski
Jul 17, 2015·Diabetes Care·Giulia FerranniniEle Ferrannini
Aug 19, 2015·JAMA : the Journal of the American Medical Association·Melanie J DaviesRalph A DeFronzo
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Dec 3, 2015·The New England Journal of Medicine·Marc A PfefferUNKNOWN ELIXA Investigators
Feb 13, 2016·Lancet·George A BrayJohn P H Wilding
Jun 14, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN LEADER Trial Investigators
Jul 15, 2016·Cell Metabolism·Matthias H TschöpRichard D DiMarchi
Jul 21, 2016·JAMA : the Journal of the American Medical Association·Suetonia C PalmerGiovanni F M Strippoli
Jul 29, 2016·The New England Journal of Medicine·Peter KühnenHeiko Krude
Sep 17, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN SUSTAIN-6 Investigators

❮ Previous
Next ❯

Citations

Mar 9, 2018·The Journal of Experimental Biology·Panna TandonJames E N Minchin
Oct 15, 2019·The Journal of Clinical Endocrinology and Metabolism·Sara Lind JepsenRune Ehrenreich Kuhre
Apr 11, 2020·The Annals of Pharmacotherapy·Ted Robert Grabarczyk, Natalie Koury Wissman
Mar 27, 2020·Frontiers in Psychology·Alberto Hernández-ReyesRafael Moreno-Rojas
Feb 6, 2020·Journal of the Endocrine Society·Emilie Balk-MøllerHannelouise Kissow
Aug 23, 2018·Diabetologia·Sally M Marshall

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiparasitics

Antiparasitics are medications which are indicated for the treatment of parasitic diseases. Discover the latest research on antiparasitics here.

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Related Papers

The Lancet. Diabetes & Endocrinology
Christian Seerup FrandsenSten Madsbad
Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia
Luca Di LulloAntonio Bellasi
© 2022 Meta ULC. All rights reserved